{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T10:36:34Z","timestamp":1784543794527,"version":"3.55.0"},"reference-count":133,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2026,12]]},"abstract":"<jats:title>Opinion statement<\/jats:title>\n                  <jats:p>Mucosal melanoma (MM) represents a rare malignancy in Caucasian populations but constitutes one of the predominant melanoma subtypes among non-Caucasian ethnic groups. Due to its anatomic occult nature, a significant proportion of patients with MM present with advanced-stage disease at diagnosis. Characterized by distinct genomic profiles and an immunosuppressive tumor microenvironment, MM exhibits suboptimal responses to current targeted drugs and immune checkpoint inhibitors (ICIs). Combination immunotherapy can overcome immune evasion by enhancing the infiltration of tumor-specific antigen-reactive T lymphocytes, thereby exhibiting potentiated anti-tumor activity. However, the rarity of MM has posed significant barriers to better understanding immunotherapy resistance mechanisms and investigating novel therapies. Consequently, there is a critical unmet need for establishing standardized treatment guidelines to improve survival outcomes in advanced MM. This article comprehensively reviews current status in the treatment of advanced MM. It also discusses potential future directions for treatment based on recent advances from clinical trials and basic research.<\/jats:p>","DOI":"10.1007\/s11864-025-01372-y","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T09:28:59Z","timestamp":1775554139000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Advanced Mucosal Melanoma Therapies: Current Status and Future Directions"],"prefix":"10.1007","volume":"27","author":[{"given":"Yiqun","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1109-3110","authenticated-orcid":false,"given":"Dawei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1870-798X","authenticated-orcid":false,"given":"Di","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,7]]},"reference":[{"issue":"34","key":"1372_CR1","doi-asserted-by":"publisher","first-page":"3977","DOI":"10.2217\/fon-2019-0465","volume":"15","author":"A Al-Haseni","year":"2019","unstructured":"Al-Haseni A, Vrable A, Qureshi MM, et al. Survival outcomes of mucosal melanoma in the USA. Future Oncol. 2019;15(34):3977\u201386. https:\/\/doi.org\/10.2217\/fon-2019-0465.","journal-title":"Future Oncol"},{"issue":"5","key":"1372_CR2","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1002\/cam4.2110","volume":"8","author":"Y Fujisawa","year":"2019","unstructured":"Fujisawa Y, Yoshikawa S, Minagawa A, et al. Clinical and histopathological characteristics and survival analysis of 4594 Japanese patients with melanoma. Cancer Med. 2019;8(5):2146\u201356. https:\/\/doi.org\/10.1002\/cam4.2110.","journal-title":"Cancer Med"},{"issue":"5","key":"1372_CR3","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1097\/cmr.000000000000000375","volume":"27","author":"T Tomizuka","year":"2017","unstructured":"Tomizuka T, Namikawa K, Higashi T. Characteristics of melanoma in Japan: a nationwide registry analysis 2011\u20132013. Melanoma Res. 2017;27(5):492\u20137. https:\/\/doi.org\/10.1097\/cmr.000000000000000375.","journal-title":"Melanoma Res"},{"issue":"2","key":"1372_CR4","doi-asserted-by":"publisher","first-page":"e95","DOI":"10.1111\/ajco.12802","volume":"14","author":"YL Teh","year":"2018","unstructured":"Teh YL, Goh WL, Tan SH, et al. Treatment and outcomes of melanoma in Asia: results from the National Cancer Centre Singapore. Asia Pac J Clin Oncol. 2018;14(2):e95-102. https:\/\/doi.org\/10.1111\/ajco.12802.","journal-title":"Asia Pac J Clin Oncol"},{"key":"1372_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-11-85","volume":"11","author":"Z Chi","year":"2011","unstructured":"Chi Z, Li S, Sheng X, et al. Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: a study of 522 consecutive cases. BMC Cancer. 2011;11:85. https:\/\/doi.org\/10.1186\/1471-2407-11-85.","journal-title":"BMC Cancer"},{"issue":"10151","key":"1372_CR6","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(18)31559-9","volume":"392","author":"D Schadendorf","year":"2018","unstructured":"Schadendorf D, van Akkooi ACJ, Berking C, et al. Melanoma. Lancet. 2018;392(10151):971\u201384.","journal-title":"Lancet"},{"issue":"3","key":"1372_CR7","doi-asserted-by":"publisher","DOI":"10.2217\/mmt-2018-0003","volume":"5","author":"H Tyrrell","year":"2018","unstructured":"Tyrrell H, Payne M. Combatting mucosal melanoma: recent advances and future perspectives. Melanoma Manag. 2018;5(3):MMT11. https:\/\/doi.org\/10.2217\/mmt-2018-0003.","journal-title":"Melanoma Manag"},{"issue":"12","key":"1372_CR8","doi-asserted-by":"publisher","first-page":"2856","DOI":"10.1158\/2159-8290.CD-22-0603","volume":"12","author":"F Newell","year":"2022","unstructured":"Newell F, Johansson PA, Wilmott JS, et al. Comparative genomics provides etiologic and biological insight into melanoma subtypes. Cancer Discov. 2022;12(12):2856\u201379. https:\/\/doi.org\/10.1158\/2159-8290.CD-22-0603.","journal-title":"Cancer Discov"},{"issue":"7","key":"1372_CR9","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1093\/oncolo\/oyae054","volume":"29","author":"D Fortman","year":"2024","unstructured":"Fortman D, Karunamurthy A, Hartman D, et al. Automated quantitative CD8+ tumor-infiltrating lymphocytes and tumor mutation burden as independent biomarkers in melanoma patients receiving front-line anti-PD-1 immunotherapy. Oncologist. 2024;29(7):619\u201328. https:\/\/doi.org\/10.1093\/oncolo\/oyae054.","journal-title":"Oncologist"},{"issue":"9","key":"1372_CR10","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1038\/labinvest.2017.64","volume":"97","author":"GJ Kaunitz","year":"2017","unstructured":"Kaunitz GJ, Cottrell TR, Lilo M, et al. Melanoma subtypes demonstrate distinct PD-L1 expression profiles. Lab Invest. 2017;97(9):1063\u201371. https:\/\/doi.org\/10.1038\/labinvest.2017.64.","journal-title":"Lab Invest"},{"issue":"11","key":"1372_CR11","doi-asserted-by":"publisher","first-page":"e424","DOI":"10.1111\/jdv.15742","volume":"33","author":"Y Nakamura","year":"2019","unstructured":"Nakamura Y, Ishitsuka Y, Tanaka R, et al. Acral lentiginous melanoma and mucosal melanoma expressed less programmed-death 1 ligand than cutaneous melanoma: a retrospective study of 73 Japanese melanoma patients. J Eur Acad Dermatol Venereol. 2019;33(11):e424-6. https:\/\/doi.org\/10.1111\/jdv.15742.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1372_CR12","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.pathol.2018.09.060","volume":"51","author":"TJ Dodds","year":"2019","unstructured":"Dodds TJ, Wilmott JS, Jackett LA, Lo SN, Long GV, Thompson JF, et al. Primary anorectal melanoma: clinical, immunohistology and DNA analysis of 43 cases. Pathology. 2019;51(1):39\u201345. https:\/\/doi.org\/10.1016\/j.pathol.2018.09.060.","journal-title":"Pathology"},{"key":"1372_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.524700","volume":"10","author":"Y Nakamura","year":"2020","unstructured":"Nakamura Y, Zhenjie Z, Oya K, et al. Poor lymphocyte infiltration to primary tumors in acral lentiginous melanoma and mucosal melanoma compared to cutaneous melanoma. Front Oncol. 2020;10:524700. https:\/\/doi.org\/10.3389\/fonc.2020.524700.","journal-title":"Front Oncol"},{"issue":"3","key":"1372_CR14","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1097\/CMR.0b013e3283457743","volume":"21","author":"JH Yi","year":"2011","unstructured":"Yi JH, Yi SY, Lee HR, Lee SI, Lim DH, Kim JH, et al. Dacarbazine-based chemotherapy as first-line treatment in noncutaneous metastatic melanoma: multicenter, retrospective analysis in Asia. Melanoma Res. 2011;21(3):223\u20137.","journal-title":"Melanoma Res"},{"issue":"7","key":"1372_CR15","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1002\/cncr.20113","volume":"100","author":"KB Kim","year":"2004","unstructured":"Kim KB, Sanguino AM, Hodges C, et al. Biochemotherapy in patients with metastatic anorectal mucosal melanoma. Cancer. 2004;100(7):1478\u201383. https:\/\/doi.org\/10.1002\/cncr.20113.","journal-title":"Cancer"},{"issue":"6","key":"1372_CR16","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1097\/00008390-200412000-00012","volume":"14","author":"MS Harting","year":"2004","unstructured":"Harting MS, Kim KB. Biochemotherapy in patients with advanced vulvovaginal mucosal melanoma. Melanoma Res. 2004;14(6):517\u201320. https:\/\/doi.org\/10.1097\/00008390-200412000-00012.","journal-title":"Melanoma Res"},{"issue":"2","key":"1372_CR17","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1097\/cmr.0b013e32835efd8d","volume":"23","author":"W Chang","year":"2013","unstructured":"Chang W, Lee SJ, Park S, et al. Effect of paclitaxel\/carboplatin salvage chemotherapy in noncutaneous versus cutaneous metastatic melanoma. Melanoma Res. 2013;23(2):147\u201351. https:\/\/doi.org\/10.1097\/cmr.0b013e32835efd8d.","journal-title":"Melanoma Res"},{"issue":"7","key":"1372_CR18","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1007\/s00262-019-02351-7","volume":"68","author":"A Moya-Plana","year":"2019","unstructured":"Moya-Plana A, Herrera G\u00f3mez RG, Rossoni C, et al. Evaluation of the efficacy of immunotherapy for non-resectable mucosal melanoma. Cancer Immunol Immunother. 2019;68(7):1171\u20138. https:\/\/doi.org\/10.1007\/s00262-019-02351-7.","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"1372_CR19","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1634\/theoncologist.2012-0464","volume":"18","author":"MA Postow","year":"2013","unstructured":"Postow MA, Luke JJ, Bluth MJ, et al. Ipilimumab for patients with advanced mucosal melanoma. Oncologist. 2013;18(6):726\u201332. https:\/\/doi.org\/10.1634\/theoncologist.2012-0464.","journal-title":"Oncologist"},{"issue":"8","key":"1372_CR20","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1111\/1346-8138.15388","volume":"47","author":"N Yamazaki","year":"2020","unstructured":"Yamazaki N, Kiyohara Y, Uhara H, et al. Real-world safety and efficacy data of ipilimumab in Japanese radically unresectable malignant melanoma patients: a postmarketing surveillance. J Dermatol. 2020;47(8):834\u201348. https:\/\/doi.org\/10.1111\/1346-8138.15388.","journal-title":"J Dermatol"},{"issue":"1","key":"1372_CR21","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ejca.2013.09.007","volume":"50","author":"M Del Vecchio","year":"2014","unstructured":"Del Vecchio M, Di Guardo L, Ascierto PA, et al. Efficacy and safety of ipilimumab 3mg\/kg in patients with pretreated, metastatic, mucosal melanoma. Eur J Cancer. 2014;50(1):121\u20137. https:\/\/doi.org\/10.1016\/j.ejca.2013.09.007.","journal-title":"Eur J Cancer"},{"issue":"6","key":"1372_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100325","volume":"6","author":"Y Nakamura","year":"2021","unstructured":"Nakamura Y, Namikawa K, Yoshikawa S, et al. Anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy in unresectable or metastatic mucosal melanoma: a retrospective, multicenter study of 329 Japanese cases (JMAC study). ESMO Open. 2021;6(6):100325. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100325.","journal-title":"ESMO Open"},{"key":"1372_CR23","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/1908065","volume":"2018","author":"C Mignard","year":"2018","unstructured":"Mignard C, Deschamps Huvier A, Gillibert A, et al. Efficacy of immunotherapy in patients with metastatic mucosal or uveal melanoma. J Oncol. 2018;2018:1908065. https:\/\/doi.org\/10.1155\/2018\/1908065.","journal-title":"J Oncol"},{"key":"1372_CR24","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.ejca.2021.08.034","volume":"157","author":"Y Umeda","year":"2021","unstructured":"Umeda Y, Yoshikawa S, Kiniwa Y, et al. Real-world efficacy of anti-PD-1 antibody or combined anti-PD-1 plus anti-CTLA-4 antibodies, with or without radiotherapy, in advanced mucosal melanoma patients: a retrospective, multicenter study. Eur J Cancer. 2021;157:361\u201372. https:\/\/doi.org\/10.1016\/j.ejca.2021.08.034.","journal-title":"Eur J Cancer"},{"issue":"4","key":"1372_CR25","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1111\/1346-8138.14227","volume":"45","author":"Y Kiyohara","year":"2018","unstructured":"Kiyohara Y, Uhara H, Ito Y, Matsumoto N, Tsuchida T, Yamazaki N. Safety and efficacy of nivolumab in Japanese patients with malignant melanoma: an interim analysis of a postmarketing surveillance. J Dermatol. 2018;45(4):408\u201315. https:\/\/doi.org\/10.1111\/1346-8138.14227.","journal-title":"J Dermatol"},{"key":"1372_CR26","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.ejca.2019.07.010","volume":"119","author":"P Nathan","year":"2019","unstructured":"Nathan P, Ascierto PA, Haanen J, et al. Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172). Eur J Cancer. 2019;119:168\u201378. https:\/\/doi.org\/10.1016\/j.ejca.2019.07.010.","journal-title":"Eur J Cancer"},{"issue":"6","key":"1372_CR27","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1038\/s41416-018-0207-6","volume":"119","author":"O Hamid","year":"2018","unstructured":"Hamid O, Robert C, Ribas A, et al. Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006. Br J Cancer. 2018;119(6):670\u20134. https:\/\/doi.org\/10.1038\/s41416-018-0207-6.","journal-title":"Br J Cancer"},{"key":"1372_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.882471","volume":"13","author":"L Si","year":"2022","unstructured":"Si L, Zhang X, Shu Y, et al. Pembrolizumab in Chinese patients with advanced melanoma: 3-year follow-up of the KEYNOTE-151 study. Front Immunol. 2022;13:882471. https:\/\/doi.org\/10.3389\/fimmu.2022.882471.","journal-title":"Front Immunol"},{"issue":"8","key":"1372_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11081133","volume":"11","author":"N Dumaz","year":"2019","unstructured":"Dumaz N, Jouenne F, Delyon J, Mourah S, Bensussan A, Lebb\u00e9 C. Atypical BRAF and NRAS mutations in mucosal melanoma. Cancers (Basel). 2019;11(8):1133. https:\/\/doi.org\/10.3390\/cancers11081133.","journal-title":"Cancers (Basel)"},{"issue":"15_suppl","key":"1372_CR30","doi-asserted-by":"publisher","first-page":"9042","DOI":"10.1200\/jco.2015.33.15_suppl.9042","volume":"33","author":"AH Bryce","year":"2015","unstructured":"Bryce AH, Arguello D, Millis SZ, et al. Multiplatform biomarker analysis on non-sun exposed mucosal melanoma. J Clin Oncol. 2015;33(15_suppl):9042\u20139042. https:\/\/doi.org\/10.1200\/jco.2015.33.15_suppl.9042.","journal-title":"J Clin Oncol"},{"key":"1372_CR31","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.semcancer.2019.09.013","volume":"61","author":"KW Nassar","year":"2020","unstructured":"Nassar KW, Tan AC. The mutational landscape of mucosal melanoma. Semin Cancer Biol. 2020;61:139\u201348. https:\/\/doi.org\/10.1016\/j.semcancer.2019.09.013.","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"1372_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-023-03032-3","volume":"23","author":"HY Wang","year":"2023","unstructured":"Wang HY, Liu Y, Deng L, et al. Clinical significance of genetic profiling based on different anatomic sites in patients with mucosal melanoma who received or did not receive immune checkpoint inhibitors. Cancer Cell Int. 2023;23(1):187. https:\/\/doi.org\/10.1186\/s12935-023-03032-3.","journal-title":"Cancer Cell Int"},{"issue":"25","key":"1372_CR33","doi-asserted-by":"publisher","first-page":"40683","DOI":"10.18632\/oncotarget.16542","volume":"8","author":"I Cosgarea","year":"2017","unstructured":"Cosgarea I, Ugurel S, Sucker A, et al. Targeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutations. Oncotarget. 2017;8(25):40683\u201392. https:\/\/doi.org\/10.18632\/oncotarget.16542.","journal-title":"Oncotarget"},{"issue":"4","key":"1372_CR34","doi-asserted-by":"publisher","first-page":"626","DOI":"10.4149\/neo_2017_419","volume":"64","author":"X Bai","year":"2017","unstructured":"Bai X, Mao LL, Chi ZH, et al. BRAF inhibitors: efficacious and tolerable in BRAF-mutant acral and mucosal melanoma. Neoplasma. 2017;64(4):626\u201332. https:\/\/doi.org\/10.4149\/neo_2017_419.","journal-title":"Neoplasma"},{"issue":"3","key":"1372_CR35","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1097\/cmr.0000000000000000345","volume":"27","author":"JD Hintzsche","year":"2017","unstructured":"Hintzsche JD, Gorden NT, Amato CM, et al. Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma. Melanoma Res. 2017;27(3):189\u201399. https:\/\/doi.org\/10.1097\/cmr.0000000000000000345.","journal-title":"Melanoma Res"},{"issue":"1","key":"1372_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11107-x","volume":"10","author":"F Newell","year":"2019","unstructured":"Newell F, Kong Y, Wilmott JS, et al. Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets. Nat Commun. 2019;10(1):3163. https:\/\/doi.org\/10.1038\/s41467-019-11107-x.","journal-title":"Nat Commun"},{"issue":"6","key":"1372_CR37","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1158\/1541-7786.MCR-20-0839","volume":"19","author":"N Broit","year":"2021","unstructured":"Broit N, Johansson PA, Rodgers CB, et al. Meta-analysis and systematic review of the genomics of mucosal melanoma. Mol Cancer Res. 2021;19(6):991\u20131004. https:\/\/doi.org\/10.1158\/1541-7786.MCR-20-0839.","journal-title":"Mol Cancer Res"},{"issue":"26","key":"1372_CR38","doi-asserted-by":"publisher","first-page":"3182","DOI":"10.1200\/JCO.2012.47.7836","volume":"31","author":"FS Hodi","year":"2013","unstructured":"Hodi FS, Corless CL, Giobbie-Hurder A, et al. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol. 2013;31(26):3182\u201390. https:\/\/doi.org\/10.1200\/JCO.2012.47.7836.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1372_CR39","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1158\/1078-0432.CCR-14-1630","volume":"21","author":"RD Carvajal","year":"2015","unstructured":"Carvajal RD, Lawrence DP, Weber JS, et al. Phase II study of nilotinib in melanoma harboring KIT alterations following progression to prior KIT inhibition. Clin Cancer Res. 2015;21(10):2289\u201396. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-1630.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1372_CR40","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/path.5017","volume":"244","author":"J Lyu","year":"2018","unstructured":"Lyu J, Song Z, Chen J, et al. Whole-exome sequencing of oral mucosal melanoma reveals mutational profile and therapeutic targets. J Pathol. 2018;244(3):358\u201366. https:\/\/doi.org\/10.1002\/path.5017.","journal-title":"J Pathol"},{"issue":"1","key":"1372_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-024-03431-x","volume":"22","author":"C Shi","year":"2024","unstructured":"Shi C, Ju H, Zhou R, et al. The efficacy and safety of dalpiciclib, a cyclin-dependent kinase 4\/6 inhibitor, in patients with advanced head and neck mucosal melanoma harboring CDK4 amplification. BMC Med. 2024;22(1):215. https:\/\/doi.org\/10.1186\/s12916-024-03431-x.","journal-title":"BMC Med"},{"issue":"10","key":"1372_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/molecules22101551","volume":"22","author":"Y Cheng","year":"2017","unstructured":"Cheng Y, Tian H. Current development status of MEK inhibitors. Molecules. 2017;22(10):1551. https:\/\/doi.org\/10.3390\/molecules22101551.","journal-title":"Molecules"},{"issue":"3","key":"1372_CR43","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S1470-2045(13)70024-X","volume":"14","author":"PA Ascierto","year":"2013","unstructured":"Ascierto PA, Schadendorf D, Berking C, et al. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol. 2013;14(3):249\u201356. https:\/\/doi.org\/10.1016\/S1470-2045(13)70024-X.","journal-title":"Lancet Oncol"},{"issue":"4","key":"1372_CR44","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/S1470-2045(17)30180-8","volume":"18","author":"R Dummer","year":"2017","unstructured":"Dummer R, Schadendorf D, Ascierto PA, et al. Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18(4):435\u201345. https:\/\/doi.org\/10.1016\/S1470-2045(17)30180-8.","journal-title":"Lancet Oncol"},{"key":"1372_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114008","volume":"202","author":"X Wei","year":"2024","unstructured":"Wei X, Zou Z, Zhang W, et al. A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma. Eur J Cancer. 2024;202:114008. https:\/\/doi.org\/10.1016\/j.ejca.2024.114008.","journal-title":"Eur J Cancer"},{"issue":"7","key":"1372_CR46","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1038\/mt.2013.79","volume":"21","author":"C Cui","year":"2013","unstructured":"Cui C, Mao L, Chi Z, et al. A phase II, randomized, double-blind, placebo-controlled multicenter trial of Endostar in patients with metastatic melanoma. Mol Ther. 2013;21(7):1456\u201363. https:\/\/doi.org\/10.1038\/mt.2013.79.","journal-title":"Mol Ther"},{"issue":"8","key":"1372_CR47","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1200\/JCO.20.00902","volume":"39","author":"X Yan","year":"2021","unstructured":"Yan X, Sheng X, Chi Z, et al. Randomized phase II study of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced mucosal melanoma. J Clin Oncol. 2021;39(8):881\u20139. https:\/\/doi.org\/10.1200\/JCO.20.00902.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1372_CR48","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1097\/cmr.000000000000000809","volume":"32","author":"L Zhou","year":"2022","unstructured":"Zhou L, Yang Y, Si L, et al. Phase II study of apatinib combined with temozolomide in patients with advanced melanoma after failure of immunotherapy. Melanoma Res. 2022;32(3):142\u20139. https:\/\/doi.org\/10.1097\/cmr.000000000000000809.","journal-title":"Melanoma Res"},{"issue":"2","key":"1372_CR49","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s10637-021-01172-9","volume":"40","author":"X Zhang","year":"2022","unstructured":"Zhang X, Jin F, Jiang S, et al. Rh-endostatin combined with chemotherapy in patients with advanced or recurrent mucosal melanoma: retrospective analysis of real-world data. Invest New Drugs. 2022;40(2):453\u201360. https:\/\/doi.org\/10.1007\/s10637-021-01172-9.","journal-title":"Invest New Drugs"},{"key":"1372_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-11-135","volume":"11","author":"L Ridolfi","year":"2013","unstructured":"Ridolfi L, Petrini M, Granato AM, et al. Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients. J Transl Med. 2013;11:135. https:\/\/doi.org\/10.1186\/1479-5876-11-135.","journal-title":"J Transl Med"},{"issue":"3","key":"1372_CR51","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/1346-8138.16925","volume":"51","author":"M Sawada","year":"2024","unstructured":"Sawada M, Hida T, Kamiya T, et al. Effects of temozolomide on tumor mutation burden and microsatellite instability in melanoma cells. J Dermatol. 2024;51(3):409\u201318. https:\/\/doi.org\/10.1111\/1346-8138.16925.","journal-title":"J Dermatol"},{"issue":"21","key":"1372_CR52","doi-asserted-by":"publisher","DOI":"10.21037\/atm-21-5738","volume":"9","author":"T Hu","year":"2021","unstructured":"Hu T, Sun W, Xu Y, et al. Combination of pembrolizumab plus temozolomide therapy in unresectable and advanced melanoma: a multicenter retrospective analysis in China. Ann Transl Med. 2021;9(21):1625. https:\/\/doi.org\/10.21037\/atm-21-5738.","journal-title":"Ann Transl Med"},{"issue":"11","key":"1372_CR53","doi-asserted-by":"publisher","first-page":"3536","DOI":"10.1158\/1078-0432.CCR-07-4025","volume":"14","author":"CT Garnett","year":"2008","unstructured":"Garnett CT, Schlom J, Hodge JW. Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement. Clin Cancer Res. 2008;14(11):3536\u201344. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-4025.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1372_CR54","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1002\/ijc.28070","volume":"133","author":"JW Hodge","year":"2013","unstructured":"Hodge JW, Garnett CT, Farsaci B, et al. Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death. Int J Cancer. 2013;133(3):624\u201336. https:\/\/doi.org\/10.1002\/ijc.28070.","journal-title":"Int J Cancer"},{"issue":"6","key":"1372_CR55","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/j.tranon.2018.08.005","volume":"11","author":"HY Ng","year":"2018","unstructured":"Ng HY, Li J, Tao L, et al. Chemotherapeutic treatments increase PD-L1 expression in esophageal squamous cell carcinoma through EGFR\/ERK activation. Transl Oncol. 2018;11(6):1323\u201333. https:\/\/doi.org\/10.1016\/j.tranon.2018.08.005.","journal-title":"Transl Oncol"},{"issue":"5","key":"1372_CR56","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1016\/j.molimm.2007.08.013","volume":"45","author":"P Zhang","year":"2008","unstructured":"Zhang P, Su DM, Liang M, Fu J. Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis. Mol Immunol. 2008;45(5):1470\u20136. https:\/\/doi.org\/10.1016\/j.molimm.2007.08.013.","journal-title":"Mol Immunol"},{"issue":"5","key":"1372_CR57","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1007\/s00432-021-03700-9","volume":"148","author":"JJ Li","year":"2022","unstructured":"Li JJ, Wang JH, Dingv Y, et al. Efficacy and safety of anti-PD-1 inhibitor combined with nab-paclitaxel in Chinese patients with refractory melanoma. J Cancer Res Clin Oncol. 2022;148(5):1159\u201369. https:\/\/doi.org\/10.1007\/s00432-021-03700-9.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"16","key":"1372_CR58","doi-asserted-by":"publisher","first-page":"9529","DOI":"10.1200\/JCO.2025.43.16_suppl.9529","volume":"43","author":"J Lin","year":"2025","unstructured":"Lin J, et al. Safety and efficacy analysis of DNV3 plus toripalimab and chemotherapy in advanced melanoma: an open-label investigator-initiated trial. J Clin Oncol. 2025;43(16):9529. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.9529.","journal-title":"J Clin Oncol"},{"key":"1372_CR59","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.598877","volume":"11","author":"SP Hack","year":"2020","unstructured":"Hack SP, Zhu AX, Wang Y. Augmenting anticancer immunity through combined targeting of angiogenic and PD-1\/PD-L1 pathways: challenges and opportunities. Front Immunol. 2020;11:598877. https:\/\/doi.org\/10.3389\/fimmu.2020.598877.","journal-title":"Front Immunol"},{"issue":"9","key":"1372_CR60","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1002\/cac2.12183","volume":"41","author":"SJ Li","year":"2021","unstructured":"Li SJ, Chen JX, Sun ZJ. Improving antitumor immunity using antiangiogenic agents: mechanistic insights, current progress, and clinical challenges. Cancer Commun. 2021;41(9):830\u201350. https:\/\/doi.org\/10.1002\/cac2.12183.","journal-title":"Cancer Commun"},{"issue":"2","key":"1372_CR61","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004036","volume":"10","author":"S Li","year":"2022","unstructured":"Li S, Wu X, Yan X, et al. Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis. J Immunother Cancer. 2022;10(2):e004036. https:\/\/doi.org\/10.1136\/jitc-2021-004036.","journal-title":"J Immunother Cancer"},{"issue":"6","key":"1372_CR62","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008611","volume":"12","author":"L Zhao","year":"2024","unstructured":"Zhao L, Ren Y, Zhang G, et al. Single-arm study of camrelizumab plus apatinib for patients with advanced mucosal melanoma. J Immunother Cancer. 2024;12(6):e008611. https:\/\/doi.org\/10.1136\/jitc-2023-008611.","journal-title":"J Immunother Cancer"},{"issue":"16","key":"1372_CR63","doi-asserted-by":"publisher","first-page":"9512","DOI":"10.1200\/JCO.2022.40.16_suppl.9512","volume":"40","author":"C Cui","year":"2022","unstructured":"Cui C, et al. Toripalimab plus axitinib versus toripalimab or axitinib alone in patients with treatment-naive unresectable or metastatic mucosal melanoma: interim results from a randomized, controlled, phase II trial. J Clin Oncol. 2022;40(16):9512. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.9512.","journal-title":"J Clin Oncol"},{"issue":"16","key":"1372_CR64","doi-asserted-by":"publisher","first-page":"9560","DOI":"10.1200\/JCO.2024.42.16_suppl.9560","volume":"42","author":"T Ye","year":"2024","unstructured":"Ye T, et al. The efficacy and safety of toripalimab combined with anlotinib in the first-line treatment of Chinese patients with metastatic melanoma. J Clin Oncol. 2024;42(16):9560. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.9560.","journal-title":"J Clin Oncol"},{"issue":"16","key":"1372_CR65","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.9553","volume":"43","author":"J Guo","year":"2025","unstructured":"Guo J, et al. First-line lenvatinib plus pembrolizumab versus placebo plus pembrolizumab in Chinese patients with unresectable or metastatic melanoma: results from LEAP-003. J Clin Oncol. 2025;43(16):9553. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.9553.","journal-title":"J Clin Oncol"},{"issue":"16","key":"1372_CR66","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.9555","volume":"43","author":"SE Lochrin","year":"2025","unstructured":"Lochrin SE, et al. Phase 2 study of axitinib + nivolumab in mucosal melanoma with pilot addition of stereotactic body radiotherapy or ipilimumab in select progressors. J Clin Oncol. 2025;43(16):9555. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.9555.","journal-title":"J Clin Oncol"},{"key":"1372_CR67","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ejca.2021.07.018","volume":"156","author":"B Tang","year":"2021","unstructured":"Tang B, Mo J, Yan X, et al. Real-world efficacy and safety of axitinib in combination with anti-programmed cell death-1 antibody for advanced mucosal melanoma. Eur J Cancer. 2021;156:83\u201392. https:\/\/doi.org\/10.1016\/j.ejca.2021.07.018.","journal-title":"Eur J Cancer"},{"issue":"21","key":"1372_CR68","doi-asserted-by":"publisher","first-page":"4642","DOI":"10.1158\/1078-0432.CCR-22-1528","volume":"28","author":"L Mao","year":"2022","unstructured":"Mao L, Fang M, Chen Y, et al. Atezolizumab plus bevacizumab in patients with unresectable or metastatic mucosal melanoma: a multicenter, open-label, single-arm phase II study. Clin Cancer Res. 2022;28(21):4642\u20138. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-1528.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"1372_CR69","doi-asserted-by":"publisher","first-page":"e1364","DOI":"10.1093\/oncolo\/oyae145","volume":"29","author":"P Rousset","year":"2024","unstructured":"Rousset P, Nardin C, Maubec E, et al. Real-world outcomes of combined lenvatinib and anti-PD-1 in advanced melanoma: the Lenvamel study, a multicenter retrospective study of the French Group of Skin Cancers (Groupe de Canc\u00e9rologie Cutan\u00e9e). Oncologist. 2024;29(10):e1364\u201372. https:\/\/doi.org\/10.1093\/oncolo\/oyae145.","journal-title":"Oncologist"},{"issue":"16","key":"1372_CR70","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.9541","volume":"41","author":"X Bai","year":"2023","unstructured":"Bai X, et al. Updated safety and efficacy results from the phase I study of either LBL-007 (an anti-LAG-3 antibody) in combination with toripalimab (an anti-PD-1 antibody) or LBL-007 in combination with toripalimab and axitinib in patients with advanced melanoma. J Clin Oncol. 2023;41(16):9541. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.9541.","journal-title":"J Clin Oncol"},{"issue":"16","key":"1372_CR71","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS9593","volume":"41","author":"D Wu","year":"2023","unstructured":"Wu D. Camrelizumab combined with anlotinib and nab-paclitaxel in patients with untreated advanced mucosal melanoma: a single-arm, multicenter, exploratory study. J Clin Oncol. 2023;41(16):TPS9593. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.TPS9593.","journal-title":"J Clin Oncol"},{"issue":"16","key":"1372_CR72","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.e21524","volume":"42","author":"X Wang","year":"2024","unstructured":"Wang X, et al. Axitinib in combination with anti\u2013PD-1 ab (pucotenlimab) plus intra-hepatic injection of oncolytic virus (OH2), in patients with mucosal melanoma and liver metastasis: an open-label phase I trial. J Clin Oncol. 2024;42(16):e21524. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.e21524.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1372_CR73","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/COC.0000000000000000239","volume":"39","author":"EI Buchbinder","year":"2016","unstructured":"Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol. 2016;39(1):98\u2013106. https:\/\/doi.org\/10.1097\/COC.0000000000000000239.","journal-title":"Am J Clin Oncol"},{"issue":"15","key":"1372_CR74","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.10019","volume":"38","author":"AN Shoushtari","year":"2020","unstructured":"Shoushtari AN, et al. Checkmate 067: long-term outcomes in patients with mucosal melanoma. J Clin Oncol. 2020;38(15):10019. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.10019.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1372_CR75","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1200\/JCO.2016.67.9258","volume":"35","author":"SP D\u2019Angelo","year":"2017","unstructured":"D\u2019Angelo SP, Larkin J, Sosman JA, et al. Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: a pooled analysis. J Clin Oncol. 2017;35(2):226\u201335. https:\/\/doi.org\/10.1200\/JCO.2016.67.9258.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1372_CR76","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16030675","volume":"16","author":"G Yin","year":"2024","unstructured":"Yin G, Guo W, Chen X, Zhang Y, Huang Z. Efficacy and mechanism of hypofractionation radiotherapy combined with PD-1 inhibitors in a model of head and neck melanoma. Cancers (Basel). 2024;16(3):675. https:\/\/doi.org\/10.3390\/cancers16030675.","journal-title":"Cancers (Basel)"},{"issue":"4","key":"1372_CR77","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1111\/1346-8138.14805","volume":"46","author":"J Kato","year":"2019","unstructured":"Kato J, Hida T, Someya M, et al. Efficacy of combined radiotherapy and anti-programmed death 1 therapy in acral and mucosal melanoma. J Dermatol. 2019;46(4):328\u201333. https:\/\/doi.org\/10.1111\/1346-8138.14805.","journal-title":"J Dermatol"},{"key":"1372_CR78","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00835","volume":"9","author":"HJ Kim","year":"2019","unstructured":"Kim HJ, Chang JS, Roh MR, et al. Effect of radiotherapy combined with pembrolizumab on local tumor control in mucosal melanoma patients. Front Oncol. 2019;9:835. https:\/\/doi.org\/10.3389\/fonc.2019.00835.","journal-title":"Front Oncol"},{"issue":"Suppl 2","key":"1372_CR79","doi-asserted-by":"publisher","first-page":"S743","DOI":"10.1016\/j.annonc.2024.08.1198","volume":"35","author":"M Nomura","year":"2024","unstructured":"Nomura M, Yoshimura M, Yokota T, Boku S, Oze I, Ishikawa H, et al. 1130P Phase II trial on nivolumab plus radiotherapy in patients with metastatic mucosal melanoma: PORTER-M3 trial. Ann Oncol. 2024;35(Suppl 2):S743. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.1198.","journal-title":"Ann Oncol"},{"issue":"565","key":"1372_CR80","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abb0391","volume":"12","author":"I M\u00e1rquez-Rodas","year":"2020","unstructured":"M\u00e1rquez-Rodas I, Longo F, Rodriguez-Ruiz ME, et al. Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti-PD-1 for patients with anti-PD-1-refractory tumors. Sci Transl Med. 2020;12(565):eabb0391. https:\/\/doi.org\/10.1126\/scitranslmed.abb0391.","journal-title":"Sci Transl Med"},{"issue":"1","key":"1372_CR81","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0568-2","volume":"7","author":"MA Aznar","year":"2019","unstructured":"Aznar MA, Planelles L, Perez-Olivares M, et al. Immunotherapeutic effects of intratumoral nanoplexed poly I:C. J Immunother Cancer. 2019;7(1):116. https:\/\/doi.org\/10.1186\/s40425-019-0568-2.","journal-title":"J Immunother Cancer"},{"issue":"25","key":"1372_CR82","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.1200\/JCO-24-02595","volume":"43","author":"I M\u00e1rquez-Rodas","year":"2025","unstructured":"M\u00e1rquez-Rodas I, Dutriaux C, Saiag P, et al. Bo-112 plus pembrolizumab for patients with anti-PD-1-resistant advanced melanoma: phase II clinical trial spotlight-203. J Clin Oncol. 2025;43(25):2806\u201315. https:\/\/doi.org\/10.1200\/JCO-24-02595.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1372_CR83","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.3390\/cells12091316","volume":"12","author":"B Ko","year":"2023","unstructured":"Ko B, Takebe N, Andrews O, Makena MR, Chen AP. Rethinking oncologic treatment strategies with interleukin-2. Cells. 2023;12(9):1316. https:\/\/doi.org\/10.3390\/cells12091316.","journal-title":"Cells"},{"issue":"8","key":"1372_CR84","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010777","volume":"13","author":"E Calvo","year":"2025","unstructured":"Calvo E, Boni V, Dumas O, et al. Nemvaleukin alfa monotherapy in patients with advanced melanoma and renal cell carcinoma: results from the phase 1\/2 non-randomized ARTISTRY-1 trial. J Immunother Cancer. 2025;13(8):e010777. https:\/\/doi.org\/10.1136\/jitc-2024-010777.","journal-title":"J Immunother Cancer"},{"issue":"5","key":"1372_CR85","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/s41423-020-0417-8","volume":"17","author":"H Li","year":"2020","unstructured":"Li H, Er Saw P, Song E. Challenges and strategies for next-generation bispecific antibody-based antitumor therapeutics. Cell Mol Immunol. 2020;17(5):451\u201361. https:\/\/doi.org\/10.1038\/s41423-020-0417-8.","journal-title":"Cell Mol Immunol"},{"issue":"8_Suppl","key":"1372_CR86","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2023-CT208","volume":"83","author":"S Lu","year":"2023","unstructured":"Lu S, et al. Abstract CT208: tebotelimab, a PD-1\/LAG-3 bispecific antibody, in patients with untreated, unresectable, recurrent or metastatic, mucosal melanoma: an open-label, single-arm, phase 1 study. Cancer Res. 2023;83(8_Suppl):CT208. https:\/\/doi.org\/10.1158\/1538-7445.AM2023-CT208.","journal-title":"Cancer Res"},{"issue":"16","key":"1372_CR87","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.9562","volume":"42","author":"Y Chen","year":"2024","unstructured":"Chen Y, et al. First-in-class PD-1\/IL-2 bispecific antibody fusion protein IBI363 in patients with advanced melanoma: safety and efficacy results from a phase I study. J Clin Oncol. 2024;42(16):9562. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.9562.","journal-title":"J Clin Oncol"},{"issue":"24","key":"1372_CR88","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1200\/JCO.21.00612","volume":"39","author":"AA Sarnaik","year":"2021","unstructured":"Sarnaik AA, Hamid O, Khushalani NI, et al. Lifileucel, a tumor-infiltrating lymphocyte therapy, in metastatic melanoma. J Clin Oncol. 2021;39(24):2656\u201366. https:\/\/doi.org\/10.1200\/JCO.21.00612.","journal-title":"J Clin Oncol"},{"issue":"12","key":"1372_CR89","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005755","volume":"10","author":"J Chesney","year":"2022","unstructured":"Chesney J, Lewis KD, Kluger H, et al. Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study. J Immunother Cancer. 2022;10(12):e005755. https:\/\/doi.org\/10.1136\/jitc-2022-005755.","journal-title":"J Immunother Cancer"},{"key":"1372_CR90","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.70050","author":"H Kluger","year":"2025","unstructured":"Kluger H, Grigoleit GU, Thomas S, et al. Lifileucel tumor-infiltrating lymphocyte cell therapy in patients with unresectable or metastatic mucosal melanoma after disease progression on immune checkpoint inhibitors. Cancer Commun. 2025. https:\/\/doi.org\/10.1002\/cac2.70050.","journal-title":"Cancer Commun"},{"issue":"11","key":"1372_CR91","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","volume":"20","author":"AD Waldman","year":"2020","unstructured":"Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol. 2020;20(11):651\u201368. https:\/\/doi.org\/10.1038\/s41577-020-0306-5.","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"1372_CR92","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1517\/14728222.2014.986459","volume":"19","author":"M Suzuki","year":"2015","unstructured":"Suzuki M, Cheung NK. Disialoganglioside GD2 as a therapeutic target for human diseases. Expert Opin Ther Targets. 2015;19(3):349\u201362. https:\/\/doi.org\/10.1517\/14728222.2014.986459.","journal-title":"Expert Opin Ther Targets"},{"issue":"6","key":"1372_CR93","doi-asserted-by":"publisher","DOI":"10.3390\/cells10061450","volume":"10","author":"T Soltantoyeh","year":"2021","unstructured":"Soltantoyeh T, Akbari B, Karimi A, et al. Chimeric antigen receptor (CAR) t cell therapy for metastatic melanoma: challenges and road ahead. Cells. 2021;10(6):1450. https:\/\/doi.org\/10.3390\/cells10061450.","journal-title":"Cells"},{"issue":"1","key":"1372_CR94","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-017-0548-2","volume":"11","author":"J Yu","year":"2018","unstructured":"Yu J, Wu X, Yan J, et al. Anti-GD2\/4-1BB chimeric antigen receptor T cell therapy for the treatment of Chinese melanoma patients. J Hematol Oncol. 2018;11(1):1. https:\/\/doi.org\/10.1186\/s13045-017-0548-2.","journal-title":"J Hematol Oncol"},{"key":"1372_CR95","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.17179\/excli2021-3522","volume":"20","author":"R Pourakbari","year":"2021","unstructured":"Pourakbari R, Hajizadeh F, Parhizkar F, Aghebati-Maleki A, Mansouri S, Aghebati-Maleki L. Co-stimulatory agonists: an insight into the immunotherapy of cancer. EXCLI J. 2021;20:1055\u201385. https:\/\/doi.org\/10.17179\/excli2021-3522.","journal-title":"EXCLI J"},{"key":"1372_CR96","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.107097","volume":"89","author":"S He","year":"2020","unstructured":"He S, Xu J, Wu J. The emerging role of co-stimulatory molecules and their agonistic mAb-based combination therapies in melanoma. Int Immunopharmacol. 2020;89:107097. https:\/\/doi.org\/10.1016\/j.intimp.2020.107097.","journal-title":"Int Immunopharmacol"},{"issue":"4","key":"1372_CR97","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0019499","volume":"6","author":"MA Curran","year":"2011","unstructured":"Curran MA, Kim M, Montalvo W, Al-Shamkhani A, Allison JP. Combination CTLA-4 blockade and 4\u20131BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production. PLoS One. 2011;6(4):e19499. https:\/\/doi.org\/10.1371\/journal.pone.0019499.","journal-title":"PLoS One"},{"issue":"2","key":"1372_CR98","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1158\/2326-6066.CIR-14-0118","volume":"3","author":"S Chen","year":"2015","unstructured":"Chen S, Lee LF, Fisher TS, et al. Combination of 4\u20131BB agonist and PD-1 antagonist promotes antitumor effector\/memory CD8 T cells in a poorly immunogenic tumor model. Cancer Immunol Res. 2015;3(2):149\u201360. https:\/\/doi.org\/10.1158\/2326-6066.CIR-14-0118.","journal-title":"Cancer Immunol Res"},{"issue":"17","key":"1372_CR99","doi-asserted-by":"publisher","first-page":"5191","DOI":"10.1158\/1078-0432.CCR-18-1550","volume":"25","author":"SA Weiss","year":"2019","unstructured":"Weiss SA, Wolchok JD, Sznol M. Immunotherapy of melanoma: facts and hopes. Clin Cancer Res. 2019;25(17):5191\u2013201. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-1550.","journal-title":"Clin Cancer Res"},{"issue":"18","key":"1372_CR100","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1200\/JCO.2016.70.1508","volume":"35","author":"HA Burris","year":"2017","unstructured":"Burris HA, Infante JR, Ansell SM, et al. Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, in patients with advanced solid tumors. J Clin Oncol. 2017;35(18):2028\u201336. https:\/\/doi.org\/10.1200\/JCO.2016.70.1508.","journal-title":"J Clin Oncol"},{"issue":"7","key":"1372_CR101","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-05961-3","volume":"14","author":"W Tang","year":"2023","unstructured":"Tang W, Chen J, Ji T, Cong X. TIGIT, a novel immune checkpoint therapy for melanoma. Cell Death Dis. 2023;14(7):466. https:\/\/doi.org\/10.1038\/s41419-023-05961-3.","journal-title":"Cell Death Dis"},{"issue":"10","key":"1372_CR102","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15102718","volume":"15","author":"DC Ziogas","year":"2023","unstructured":"Ziogas DC, Theocharopoulos C, Lialios PP, et al. Beyond CTLA-4 and PD-1 inhibition: novel immune checkpoint molecules for melanoma treatment. Cancers (Basel). 2023;15(10):2718. https:\/\/doi.org\/10.3390\/cancers15102718.","journal-title":"Cancers (Basel)"},{"issue":"12","key":"1372_CR103","doi-asserted-by":"publisher","first-page":"5949","DOI":"10.1158\/0008-5472.CAN-06-4249","volume":"67","author":"T Raskovalova","year":"2007","unstructured":"Raskovalova T, Lokshin A, Huang X, et al. Inhibition of cytokine production and cytotoxic activity of human antimelanoma specific CD8+ and CD4+ T lymphocytes by adenosine-protein kinase A type I signaling. Cancer Res. 2007;67(12):5949\u201356. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-4249.","journal-title":"Cancer Res"},{"key":"1372_CR104","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.837230","volume":"13","author":"C Sun","year":"2022","unstructured":"Sun C, Wang B, Hao S. Adenosine-A2A receptor pathway in cancer immunotherapy. Front Immunol. 2022;13:837230. https:\/\/doi.org\/10.3389\/fimmu.2022.837230.","journal-title":"Front Immunol"},{"issue":"6","key":"1372_CR105","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1158\/2326-6066.CIR-14-0072","volume":"2","author":"JL Lines","year":"2014","unstructured":"Lines JL, Sempere LF, Broughton T, Wang L, Noelle R. VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy. Cancer Immunol Res. 2014;2(6):510\u20137. https:\/\/doi.org\/10.1158\/2326-6066.CIR-14-0072.","journal-title":"Cancer Immunol Res"},{"issue":"3","key":"1372_CR106","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1053\/j.seminoncol.2015.02.015","volume":"42","author":"K Baksh","year":"2015","unstructured":"Baksh K, Weber J. Immune checkpoint protein inhibition for cancer: preclinical justification for CTLA-4 and PD-1 blockade and new combinations. Semin Oncol. 2015;42(3):363\u201377. https:\/\/doi.org\/10.1053\/j.seminoncol.2015.02.015.","journal-title":"Semin Oncol"},{"issue":"1","key":"1372_CR107","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/imr.12520","volume":"276","author":"M Das","year":"2017","unstructured":"Das M, Zhu C, Kuchroo VK. Tim-3 and its role in regulating anti-tumor immunity. Immunol Rev. 2017;276(1):97\u2013111. https:\/\/doi.org\/10.1111\/imr.12520.","journal-title":"Immunol Rev"},{"issue":"1","key":"1372_CR108","doi-asserted-by":"publisher","DOI":"10.1016\/j.omton.2024.200773","volume":"32","author":"C Lu","year":"2024","unstructured":"Lu C, Tan Y. Promising immunotherapy targets: TIM3, LAG3, and TIGIT joined the party. Mol Ther Oncolytics. 2024;32(1):200773. https:\/\/doi.org\/10.1016\/j.omton.2024.200773.","journal-title":"Mol Ther Oncolytics"},{"key":"1372_CR109","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.681320","volume":"12","author":"JB Lee","year":"2021","unstructured":"Lee JB, Ha SJ, Kim HR. Clinical insights into novel immune checkpoint inhibitors. Front Pharmacol. 2021;12:681320. https:\/\/doi.org\/10.3389\/fphar.2021.681320.","journal-title":"Front Pharmacol"},{"key":"1372_CR110","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102461","volume":"110","author":"Y Fujiwara","year":"2022","unstructured":"Fujiwara Y, Kato S, Nesline MK, et al. Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy. Cancer Treat Rev. 2022;110:102461. https:\/\/doi.org\/10.1016\/j.ctrv.2022.102461.","journal-title":"Cancer Treat Rev"},{"key":"1372_CR111","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.785091","volume":"12","author":"AP Shi","year":"2022","unstructured":"Shi AP, Tang XY, Xiong YL, et al. Immune checkpoint LAG3 and its ligand FGL1 in cancer. Front Immunol. 2022;12:785091. https:\/\/doi.org\/10.3389\/fimmu.2021.785091.","journal-title":"Front Immunol"},{"issue":"2","key":"1372_CR112","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1080\/14728214.2021.1901884","volume":"26","author":"V Vanella","year":"2021","unstructured":"Vanella V, Festino L, Vitale MG, Alfano B, Ascierto PA. Emerging PD-1\/PD-L1 antagonists for the treatment of malignant melanoma. Expert Opin Emerg Drugs. 2021;26(2):79\u201392. https:\/\/doi.org\/10.1080\/14728214.2021.1901884.","journal-title":"Expert Opin Emerg Drugs"},{"issue":"11","key":"1372_CR113","doi-asserted-by":"publisher","first-page":"983","DOI":"10.2217\/imt-2018-0200","volume":"11","author":"S Chen","year":"2019","unstructured":"Chen S, Wainwright DA, Wu JD, et al. CD73: an emerging checkpoint for cancer immunotherapy. Immunotherapy. 2019;11(11):983\u201397. https:\/\/doi.org\/10.2217\/imt-2018-0200.","journal-title":"Immunotherapy"},{"issue":"12","key":"1372_CR114","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1158\/1078-0432.CCR-24-3164","volume":"31","author":"Y Li","year":"2025","unstructured":"Li Y, Cui Z, Song X, et al. Single-cell transcriptomic landscape deciphers intratumoral heterogeneity and subtypes of acral and mucosal melanomas. Clin Cancer Res. 2025;31(12):2495\u2013514. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-3164.","journal-title":"Clin Cancer Res"},{"key":"1372_CR115","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2024.122691","volume":"348","author":"Y Bao","year":"2024","unstructured":"Bao Y, Tong C, Xiong X. CXCL3: a key player in tumor microenvironment and inflammatory diseases. Life Sci. 2024;348:122691. https:\/\/doi.org\/10.1016\/j.lfs.2024.122691.","journal-title":"Life Sci"},{"issue":"20","key":"1372_CR116","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1182\/blood-2018-11-844548","volume":"133","author":"MA Giese","year":"2019","unstructured":"Giese MA, Hind LE, Huttenlocher A. Neutrophil plasticity in the tumor microenvironment. Blood. 2019;133(20):2159\u201367. https:\/\/doi.org\/10.1182\/blood-2018-11-844548.","journal-title":"Blood"},{"issue":"10","key":"1372_CR117","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.1016\/j.apsb.2021.01.003","volume":"11","author":"M Jiang","year":"2021","unstructured":"Jiang M, Jia K, Wang L, et al. Alterations of DNA damage response pathway: biomarker and therapeutic strategy for cancer immunotherapy. Acta Pharm Sin B. 2021;11(10):2983\u201394. https:\/\/doi.org\/10.1016\/j.apsb.2021.01.003.","journal-title":"Acta Pharm Sin B"},{"issue":"3","key":"1372_CR118","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/mc.23368","volume":"61","author":"X Chen","year":"2022","unstructured":"Chen X, Ou Z, Wang L, et al. Association of tumor mutational burden with genomic alterations in Chinese urothelial carcinoma. Mol Carcinog. 2022;61(3):311\u201321. https:\/\/doi.org\/10.1002\/mc.23368.","journal-title":"Mol Carcinog"},{"issue":"9","key":"1372_CR119","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a012716","volume":"5","author":"A Mar\u00e9chal","year":"2013","unstructured":"Mar\u00e9chal A, Zou L. DNA damage sensing by the ATM and ATR kinases. Cold Spring Harb Perspect Biol. 2013;5(9):a012716. https:\/\/doi.org\/10.1101\/cshperspect.a012716.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"2","key":"1372_CR120","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.annonc.2021.10.009","volume":"33","author":"R Kim","year":"2022","unstructured":"Kim R, Kwon M, An M, et al. Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced\/metastatic melanoma who have failed prior anti-PD-1 therapy. Ann Oncol. 2022;33(2):193\u2013203. https:\/\/doi.org\/10.1016\/j.annonc.2021.10.009.","journal-title":"Ann Oncol"},{"issue":"17","key":"1372_CR121","doi-asserted-by":"publisher","first-page":"4700","DOI":"10.1158\/1078-0432.CCR-21-0251","volume":"27","author":"ST Kim","year":"2021","unstructured":"Kim ST, Smith SA, Mortimer P, et al. Phase I study of ceralasertib (AZD6738), a novel DNA damage repair agent, in combination with weekly paclitaxel in refractory cancer. Clin Cancer Res. 2021;27(17):4700\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-0251.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1372_CR122","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-019-0784-8","volume":"12","author":"A Li","year":"2019","unstructured":"Li A, Yi M, Qin S, Chu Q, Luo S, Wu K. Prospects for combining immune checkpoint blockade with PARP inhibition. J Hematol Oncol. 2019;12(1):98. https:\/\/doi.org\/10.1186\/s13045-019-0784-8.","journal-title":"J Hematol Oncol"},{"key":"1372_CR123","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00570","volume":"10","author":"P Vikas","year":"2020","unstructured":"Vikas P, Borcherding N, Chennamadhavuni A, Garje R. Therapeutic potential of combining PARP inhibitor and immunotherapy in solid tumors. Front Oncol. 2020;10:570. https:\/\/doi.org\/10.3389\/fonc.2020.00570.","journal-title":"Front Oncol"},{"issue":"6","key":"1372_CR124","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","volume":"19","author":"A Garcia-Diaz","year":"2017","unstructured":"Garcia-Diaz A, Shin DS, Moreno BH, et al. Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression. Cell Rep. 2017;19(6):1189\u2013201. https:\/\/doi.org\/10.1016\/j.celrep.2017.04.031.","journal-title":"Cell Rep"},{"issue":"1","key":"1372_CR125","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01883-9","volume":"8","author":"H Sato","year":"2017","unstructured":"Sato H, Niimi A, Yasuhara T, et al. DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells. Nat Commun. 2017;8(1):1751. https:\/\/doi.org\/10.1038\/s41467-017-01883-9.","journal-title":"Nat Commun"},{"issue":"1","key":"1372_CR126","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/cas.13424","volume":"109","author":"K Mimura","year":"2018","unstructured":"Mimura K, Teh JL, Okayama H, et al. PD-L1 expression is mainly regulated by interferon gamma associated with JAK-STAT pathway in gastric cancer. Cancer Sci. 2018;109(1):43\u201353. https:\/\/doi.org\/10.1111\/cas.13424.","journal-title":"Cancer Sci"},{"issue":"5","key":"1372_CR127","doi-asserted-by":"publisher","DOI":"10.3390\/cells9051135","volume":"9","author":"P Donizy","year":"2020","unstructured":"Donizy P, Wu CL, Mull J, et al. Up-regulation of PARP1 expression significantly correlated with poor survival in mucosal melanomas. Cells. 2020;9(5):1135. https:\/\/doi.org\/10.3390\/cells9051135.","journal-title":"Cells"},{"issue":"7","key":"1372_CR128","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13071648","volume":"13","author":"JB Loureiro","year":"2021","unstructured":"Loureiro JB, Raimundo L, Calheiros J, et al. Targeting p53 for melanoma treatment: counteracting tumour proliferation, dissemination and therapeutic resistance. Cancers (Basel). 2021;13(7):1648. https:\/\/doi.org\/10.3390\/cancers13071648.","journal-title":"Cancers (Basel)"},{"issue":"12","key":"1372_CR129","doi-asserted-by":"publisher","first-page":"3548","DOI":"10.1158\/1078-0432.CCR-18-3442","volume":"25","author":"R Zhou","year":"2019","unstructured":"Zhou R, Shi C, Tao W, et al. Analysis of mucosal melanoma whole-genome landscapes reveals clinically relevant genomic aberrations. Clin Cancer Res. 2019;25(12):3548\u201360. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-3442.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1372_CR130","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12030540","volume":"12","author":"A Forschner","year":"2020","unstructured":"Forschner A, Hilke FJ, Bonzheim I, et al. MDM2, MDM4 and EGFR amplifications and hyperprogression in metastatic acral and mucosal melanoma. Cancers (Basel). 2020;12(3):540. https:\/\/doi.org\/10.3390\/cancers12030540.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"1372_CR131","doi-asserted-by":"publisher","DOI":"10.3390\/ph16010024","volume":"16","author":"A Aguilar","year":"2022","unstructured":"Aguilar A, Wang S. Therapeutic strategies to activate p53. Pharmaceuticals (Basel). 2022;16(1):24. https:\/\/doi.org\/10.3390\/ph16010024.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"1","key":"1372_CR132","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0750-6","volume":"7","author":"DD Fang","year":"2019","unstructured":"Fang DD, Tang Q, Kong Y, et al. MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment. J Immunother Cancer. 2019;7(1):327. https:\/\/doi.org\/10.1186\/s40425-019-0750-6.","journal-title":"J Immunother Cancer"},{"issue":"16","key":"1372_CR133","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.2506","volume":"39","author":"AW Tolcher","year":"2021","unstructured":"Tolcher AW, et al. Preliminary results of a phase II study of alrizomadlin (APG-115), a novel, small-molecule MDM2 inhibitor, in combination with pembrolizumab in patients (pts) with unresectable or metastatic melanoma or advanced solid tumors that have failed immuno-oncologic (I-O) drugs. J Clin Oncol. 2021;39(16):15. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.2506.","journal-title":"J Clin Oncol"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-025-01372-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-025-01372-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-025-01372-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T09:29:02Z","timestamp":1775554142000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-025-01372-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,7]]},"references-count":133,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["1372"],"URL":"https:\/\/doi.org\/10.1007\/s11864-025-01372-y","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,7]]},"assertion":[{"value":"22 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any\u00a0studies with human or animal subjects performed by any of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"20"}}